Top Losers

  Regulus Therapeutics Inc (NASDAQ: RGLS) shares dropped 45.6 percent to $2.72 after the FDA said it had placed the company’s lead product candidate, RG-101 for the treatment of hepatitis C virus (HCV) infection, on clinical hold. Celyad SA (ADR) (NASDAQ: CYAD) shares fell 36....

  Barclays PLC (ADR) (NYSE: BCS) shares dipped 20.6 percent to $7.06 after declining 20.48 percent on Friday. BofA/Merrill Lynch downgraded Barclays from Buy to Neutral, while JP Morgan also downgraded the stock to Neutral. Cobalt International Energy, Inc. (NYSE: CIE) shares fell...

  Sonic Corporation (NASDAQ: SONC) shares fell 9 percent to $27.56. Sonic reported better-than-expected earnings for its third quarter, but the company missed analysts’ sales estimates. Same-store sales rose by only 2 percent over the period, while analysts were expecting a 2.7...

  Skypeople Fruit Juice Inc (NASDAQ: SPU) shares dipped 13.6 percent to $2.32. CACI International Inc (NYSE: CACI) shares dropped 7.9 percent to $91.56 after the company issued a weak forecast for 2017. Whiting Petroleum Corp (NYSE: WLL) shares declined 7.7 percent to $11.17 as the...

  CVD Equipment Corporation (NASDAQ: CVV) shares jumped 21.13 percent to $8.37 after the company reported that it has received a $30 million order from major aviation component supplier. Ocwen Financial Corp (NYSE: OCN) shares gained 12.1 percent to $ 1.76 after the company announced...

  Emergent Biosolutions Inc (NYSE: EBS) shares dropped 21.54 percent to $30.85 after the company reported that the U.S. Department of Health and Human Services issued two solicitation notices with respect to the development and procurement of anthrax vaccines for the Strategic National...

  Medgenics Inc (NYSE: MDGN) shares tumbled 15.06 percent to $5.30. Medgenics priced public offering of 3.64 million shares at $5.50 per share. SCYNEXIS Inc (NASDAQ: SCYX) shares dropped 13.96 percent to $2.28. SCYNEXIS priced public offering of 9.375 million shares of its common...

  GlobeImmune Inc (NASDAQ: GBIM) shares tumbled 22.72 percent to $2.55. Vista Gold Corp. (NYSE: VGZ) shares fell 10.34 percent to $1.30. Gold futures declined 0.51 percent to $1,288.30 an ounce. Eagle Pharmaceuticals Inc (NASDAQ: EGRX) shares dropped 10.32 percent to $40.15....

  GlycoMimetics Inc (NASDAQ: GLYC) shares fell 18.69 percent to $5.99. GlycoMimetics priced public offering of 3.3 million shares at $6.10 per share. Innocoll Holdings PLC (NASDAQ: INNL) shares declined 14.90 percent to $6.26. Innocoll Holdings priced its 5.725 million share offering...

  Korn/Ferry International (NYSE: KFY) shares dropped 19.99 percent to $22.10. Korn/Ferry posted upbeat results for its fourth quarter, but issued a weak earnings forecast. Baird downgraded Korn/Ferry from Outperform to Neutral. Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP)...

  Carbylan Therapeutics Inc (NASDAQ: CBYL) shares dropped 21.29 percent to $0.90 following announcement of share purchase agreement with KalVista Pharmaceuticals. KalVista will become wholly-owned subsidary of Carbylan. Leading Brands, Inc (USA) (NASDAQ: LBIX) shares declined 15.81...

  Infinity Pharmaceuticals Inc. (NASDAQ: INFI) shares dipped 70.63 percent to $1.29. Infinity announced plans to cut 21 percent of the workforce. The company also reported that DYNAMO Phase 2 monotherapy study evaluating the efficacy and safety of duvelisib met its primary endpoint....

Health Insurance Innovations Inc (NASDAQ: HIIQ) shares fell 25.21 percent to $5.25. Raymond James downgraded Health Insurance Innovations from Strong Buy to Market Perform. SCYNEXIS Inc (NASDAQ: SCYX) shares tumbled 23.84 percent to $3.13 as the company reported top-line results in its proof-of-...

Gainers Envision Healthcare Holdings Inc (NYSE: EVHC) shares rose 9.16 percent to $28.00 in pre-market trading. Envision Healthcare is said to be in discussions with Amsurg Corp (NASDAQ: AMSG), regarding a potential merger, according to sources as reported by Dow Jones on Wednesday. A deal...

Fibrocell Science Inc (NASDAQ: FCSC) shares tumbled 39.70 percent to $1.20 after the company revealed that the primary endpoints were not met in its second stage clinical trial of azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. VeriFone Systems Inc (...